Latest news with #Plasmodiumfalciparum
Hans India
20 hours ago
- Health
- Hans India
India developing indigenous multi-stage Malaria vaccine 'AdFalciVax'
New Delhi: India has taken a major step forward in the fight against malaria with the development of a new indigenous vaccine candidate called AdFalciVax. This vaccine is being developed by the Indian Council of Medical Research (ICMR), through its institutes RMRC Bhubaneswar and the National Institute of Malaria Research (NIMR), in partnership with the Department of Biotechnology's National Institute of Immunology (DBT-NII). AdFalciVax is a unique malaria vaccine that targets two key stages of Plasmodium falciparum, the parasite responsible for the deadliest form of malaria. Most existing vaccines only focus on one stage of the parasite's life cycle, but AdFalciVax is designed to provide stronger and longer-lasting protection by targeting both the human infection stage and the stage responsible for transmission through mosquitoes. In early lab testing, the vaccine has shown excellent results. Scientists believe that it could offer several benefits over current vaccines like RTS, S/AS01 and R21/Matrix-M. These include broader protection, reduced chances of the parasite escaping the immune response, and improved long-term immunity. The vaccine also remains stable for over nine months at room temperature, making it easier to store and transport, especially in tropical regions. Additionally, it uses cost-effective ingredients like alum, which is commonly used as an adjuvant in vaccines. The vaccine is currently in the preclinical stage. If everything goes as planned, it could take around seven years for the vaccine to be ready for public use. The development timeline includes manufacturing under strict safety standards, clinical trials, and regulatory approvals. One of the key innovations of AdFalciVax is that it is made using 'Lactococcus lactis', a safe and well-known bacteria used in vaccine development. Its design makes it capable of protecting individuals from getting sick while also reducing the spread of malaria within communities. The ICMR plans to offer the vaccine technology to other organisations and manufacturers under non-exclusive agreements. This means multiple companies can work on producing the vaccine, helping it reach more people faster once approved. AdFalciVax is being developed entirely in India, supporting the government's 'Make in India' initiative.
Economic Times
a day ago
- Health
- Economic Times
Development of indigenous multi-stage Malaria vaccine 'AdFalciVax' is underway
The Indian Council of Medical Research (ICMR), through its Regional Medical Research Centre, Bhubaneswar (RMRCBB) and National Institute of Malaria Research (NIMR), in partnership with the Department of Biotechnology-National Institute of Immunology (DBT-NII), is currently developing a novel recombinant chimeric malaria vaccine candidate, named AdFalciVax. ADVERTISEMENT AdFalciVax is the first indigenous recombinant chimeric malaria vaccine specifically designed to target two critical stages of Plasmodium falciparum, the parasite responsible for the most lethal form of malaria. The vaccine aims to protect against human infection while also reducing vector-borne community transmission of the parasite. According to the release, the vaccine has demonstrated excellent efficacy in the preclinical stage of development. Preclinical data suggest that AdFalciVax may have advantages over existing single-stage vaccines, including broader protection by targeting two vulnerable parasite stages, lower risk of immune evasion, potential for better long-term immunity, and extended thermal stability with functionality maintained for over nine months at room is a recombinant multistage vaccine produced in Lactococcus lactis, designed to protect both individual humans and reduce the community transmission represents one of the most advanced malaria vaccine candidates globally, with a rational design targeting two key stages of the parasite. This vaccine consists of a stable and functional recombinant chimaera between antigenic components that promises dual protection. ADVERTISEMENT ICMR intends to license the technology for AdFalciVax to eligible organisations and manufacturers for further development, manufacture, and commercialisation under non-exclusive agreements. This approach aims to enable wider outreach and maximise public health benefits. All collaborations will adhere to ICMR's Intellectual Property Policy. ADVERTISEMENT As an indigenously developed vaccine candidate that fulfils the Make in India mandate, AdFalciVax holds the potential to contribute substantially to malaria eradication by preventing infection and minimising community information is provided for awareness purposes only. The vaccine candidate is in its early research and development phases and is not yet available for any clinical use or commercialisation. ADVERTISEMENT (You can now subscribe to our Economic Times WhatsApp channel)
Time of India
a day ago
- Health
- Time of India
Development of indigenous multi-stage Malaria vaccine 'AdFalciVax' is underway
The Indian Council of Medical Research (ICMR), through its Regional Medical Research Centre, Bhubaneswar (RMRCBB) and National Institute of Malaria Research (NIMR), in partnership with the Department of Biotechnology-National Institute of Immunology (DBT-NII), is currently developing a novel recombinant chimeric malaria vaccine candidate, named AdFalciVax . AdFalciVax is the first indigenous recombinant chimeric malaria vaccine specifically designed to target two critical stages of Plasmodium falciparum, the parasite responsible for the most lethal form of malaria. Explore courses from Top Institutes in Select a Course Category Design Thinking Product Management others Healthcare Cybersecurity Project Management Management Data Analytics Degree PGDM Public Policy Operations Management Artificial Intelligence MBA Finance Digital Marketing Technology Data Science healthcare MCA Data Science CXO Others Leadership Skills you'll gain: Duration: 22 Weeks IIM Indore CERT-IIMI DTAI Async India Starts on undefined Get Details Skills you'll gain: Duration: 25 Weeks IIM Kozhikode CERT-IIMK PCP DTIM Async India Starts on undefined Get Details The vaccine aims to protect against human infection while also reducing vector-borne community transmission of the parasite. According to the release, the vaccine has demonstrated excellent efficacy in the preclinical stage of development. Preclinical data suggest that AdFalciVax may have advantages over existing single-stage vaccines, including broader protection by targeting two vulnerable parasite stages, lower risk of immune evasion, potential for better long-term immunity, and extended thermal stability with functionality maintained for over nine months at room temperature. AdFalciVax is a recombinant multistage vaccine produced in Lactococcus lactis, designed to protect both individual humans and reduce the community transmission cycle. Live Events It represents one of the most advanced malaria vaccine candidates globally, with a rational design targeting two key stages of the parasite. This vaccine consists of a stable and functional recombinant chimaera between antigenic components that promises dual protection. ICMR intends to license the technology for AdFalciVax to eligible organisations and manufacturers for further development, manufacture, and commercialisation under non-exclusive agreements. This approach aims to enable wider outreach and maximise public health benefits. All collaborations will adhere to ICMR's Intellectual Property Policy. As an indigenously developed vaccine candidate that fulfils the Make in India mandate, AdFalciVax holds the potential to contribute substantially to malaria eradication by preventing infection and minimising community transmission. This information is provided for awareness purposes only. The vaccine candidate is in its early research and development phases and is not yet available for any clinical use or commercialisation.
The Hindu
2 days ago
- Health
- The Hindu
ICMR seeks collaboration for malaria vaccine production through tech transfer
Indian Council of Medical Research (ICMR), Delhi, has invited Expression of Interest (EoI) from eligible organisations, companies and manufacturers for undertaking 'Transfer of Technology' for commercialisation of 'a recombinant chimeric multi-stage malaria vaccine (AdFalciVax) against Plasmodium falciparum' useful in preventing Plasmodium falciparum infection in humans and minimizing its community transmission. The goal is to facilitate the commercialisation of this vaccine to prevent and minimize malaria transmission, and the EoI is open until August 17. The Council noted that it would provide technical support through its team of experienced scientists in study planning, product development, development of study protocol, results/data analysis, outcome assessment, safety and efficacy assessment, product improvement, etc., if deemed fit upon mutual understanding between ICMR and the collaborative company. Additionally, while the Council will have no financial implications unless otherwise specified, its Institutes would provide support and facilitation to conduct the research and development (R&D)/clinical study of new technology/product in India through its affiliates/institutes, in collaboration with the company/institutions. It would also provide technical support in development of technology/product and will also facilitate the validation, if required. 'ICMR-Regional Medical Research Centre, Bhubaneswar (ICMR-RMRCBB) is one of the four constituent institutes that has led the development of the technology and has technical-know-how of the process to produce this recombinant chimeric multi-stage malaria vaccine in Lactococcus lactis. The pre-clinical validation of this technology was conducted in collaboration with ICMR-National Institute of Malaria Research (ICMR-NIMR), another constituent institute of ICMR, and National Institute of Immunology (NII), New Delhi, an autonomous research institute of the Department of Biotechnology,' it added.
New Indian Express
3 days ago
- Health
- New Indian Express
RMRC Bhubaneswar develops advanced malaria vaccine, ready for tech transfer
BHUBANESWAR: In a significant breakthrough, a team of researchers led by the Regional Medical Research Centre (RMRC), Bhubaneswar, has developed a novel and advanced malaria vaccine that can prevent Plasmodium falciparum infection in humans and community transmission. The new recombinant, chimeric multi-stage vaccine code-named AdFalciVax has been designed to protect against the deadliest malaria parasite in humans. It is now ready for technology transfer to manufacturers for production, clinical trials and its commercialisation. Currently, two malaria vaccines are available and cost in a range of `250 to `830 per dose. The efficacy rate is between 33 per cent and 67 per cent. Unlike existing WHO-recommended vaccines RTS,S/AS01 (Mosquirix) and R21/Matrix-M, AdFalciVax offers dual-stage protection and is cost-effective. Scientist-D at RMRC Dr Susheel Singh said the new vaccine can prevent human infection and interrupt transmission in the community. 'AdFalciVax uses a full-length PfCSP, a major protein found in Pf, for broader protection and includes a novel fusion of Pfs230 and Pfs48/45 proteins to produce strong antibodies that stop the transmission,' he said. What makes AdFalciVax stand out among the existing vaccines is its exceptional pharmaceutical stability. The formulation remains potent for over nine months at room temperature, eliminating the need for costly cold chain logistics, which continue to be a major bottleneck in vaccine distribution across remote and resource-limited regions. According to the researchers, the vaccine has been developed with the help of cutting-edge protein engineering using Lactococcus lactis, a safe bacterial host. The pre-clinical validation of the technology has been conducted by RMRC in collaboration with National Institute of Malaria Research (NIMR) and National Institute of Immunology (NII), New Delhi. RMRC director Dr Sanghamitra Pati said, 'The vaccine's efficacy was sustained for over four months post-boost, which translates to over a decade of protection in humans.' Meanwhile, Indian Council of Medical Research (ICMR), New Delhi has invited expressions of interest from the eligible organisations, companies and manufacturers for transfer of technology and commercialisation.
